PetNet inks radiopharma deal with Lantheus
Radiopharmaceutical provider PetNet Solutions, a wholly owned subsidiary of Siemens Medical Solutions, has executed a supply agreement with Lantheus Medical Imaging, a contrast agent and biomarker developer, to provide BMS747158 for PET imaging of cardiac perfusion as part of a Phase II and Phase III trial.
PetNet and Siemens have previously supplied all of the clinical trial doses for the Lantheus phase I study, the company said. BMS747158 is Lantheus' novel fluorine 18-labeled PET tracer for myocardial perfusion imaging in subjects under rest and stress conditions.
The Toronto-based PetNet operates a network with 52 radiopharmacies and distribution centers that manufacture and distribute PET biomarkers to hospitals, clinics and research facilities.
PetNet and Siemens have previously supplied all of the clinical trial doses for the Lantheus phase I study, the company said. BMS747158 is Lantheus' novel fluorine 18-labeled PET tracer for myocardial perfusion imaging in subjects under rest and stress conditions.
The Toronto-based PetNet operates a network with 52 radiopharmacies and distribution centers that manufacture and distribute PET biomarkers to hospitals, clinics and research facilities.